v3.25.1
Description of the Business (Details) - USD ($)
$ in Millions
 1 Months Ended
Jul. 31, 2024
Oct. 28, 2024
Restructuring Cost and Reserve [Line Items]    
Percentage of reduction in workforce under corporate restructuring 80.00%  
Net cash at closing of the merger   $ 1.0
Private Placement    
Restructuring Cost and Reserve [Line Items]    
Aggregate purchase price   $ 200.0
Prior to closing of private placement | Crescent Biopharma, Inc.    
Restructuring Cost and Reserve [Line Items]    
Parent ownership (as percentage)   86.20%
Prior to closing of private placement | GlycoMimetics, Inc.    
Restructuring Cost and Reserve [Line Items]    
Noncontrolling ownership (as percentage)   13.80%
Post the Closing of Private Placement [Member] | Crescent Biopharma, Inc.    
Restructuring Cost and Reserve [Line Items]    
Parent ownership (as percentage)   97.40%
Post the Closing of Private Placement [Member] | GlycoMimetics, Inc.    
Restructuring Cost and Reserve [Line Items]    
Noncontrolling ownership (as percentage)   2.60%